| 2024-12-09 |
Synthekine |
Results Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting synthekine.com ↗
This regimen also demonstrated durable responses, including complete responses in all 4 patients with non-Hodgkin lymphoma (NHL). |
| 2024-11-15 |
Synthekine |
Results Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 synthekine.com ↗
|
| 2024-09-04 |
Synthekine |
Regulatory Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion synthekine.com ↗
Fast Track designation follows Investigational New Drug (IND) clearance for a Phase 1 study evaluating SYNCAR-001 + STK-009 for non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN) |
| 2024-03-20 |
Synthekine |
Regulatory Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion synthekine.com ↗
|
| 2021-12-23 |
Synthekine |
Results Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System synthekine.com ↗
The published data shows STK-009, the orthogonal IL-2 ligand, enables the control of cell expansion and activation of a CD19 CAR-T cell therapy which expresses the orthogonal IL-2 receptor (SYNCAR-001) in preclinical models of human lymphoma. |
| 2021-11-16 |
Synthekine |
Results Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities synthekine.com ↗
Synthekine also presented new data on its orthogonal IL-2 and CD-19 CAR-T system (STK-009 and SYNCAR-001). |
| 2021-11-16 |
Synthekine |
Results Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T synthekine.com ↗
In both disseminated and subcutaneous RAJI lymphoma models in mice evaluating the efficacy of STK-009 with SYNCAR-001, STK-009 dosing drove increased levels of circulating SYNCAR-001 cells, resulting in complete responses. |